Memeo Riccardo, Laurenzi Andrea, Pittau Gabriella, Sanchez-Cabus Santiago, Vibert Eric, Adam Rene, Azoulay Daniel, Cunha Antonio Sa, Ichai Philippe, Saliba Faouzi, Samuel Didier, Cherqui Daniel, Castaing Denis
Centre Hépato-biliaire, Paul Brousse Hospital, Université Paris Sud, Villejuif, France.
HPB Surgery and Transplantation Department, ICMDiM, Hospital Clinic de Barcelona, Barcelona, Spain.
Clin Transplant. 2016 Mar;30(3):312-9. doi: 10.1111/ctr.12691. Epub 2016 Feb 9.
Liver retransplantation remains the only option for recurrent graft failure. The aim of our study is to identify predictive factors involved in patients and graft survival for patients undergoing repeat retransplantation (RRT).
From January 1985 to December 2012, 2940 liver transplantations were performed in 2477 patients at Paul Brousse Hospital, Villejuif, France. All patients who underwent third, fourth, and fifth transplantation were included in the study and retrospectively analyzed.
In the univariate analysis, the factors that were associated with 90-d patient post-operative survival were pre-operative vasopressors support, pre-operative extra hepatic sepsis, primary non-function (PNF) as indication of RRT, recipient's model of end stage liver disease (MELD), urgent RRT, creatinine value at RRT, and prothrombin ratio. The multivariate logistic regression confirmed the role of systemic septic status (OR = 12.8, p = 0.01) and vasopressor drug support (OR = 4.7, p = 0.05) as predictors of post-operative mortality. In the univariate analysis, the factors that were associated with patient 10 yr long-term survival (were vasopressor support, systemic septic patient, PNF as indication of RRT, RRT occurred between 1985 and 1999, recipient's MELD, creatinine value at RRT, and prothrombin ratio. The multivariate logistic regression confirmed the role of systemic septic patient (OR = 6.4, p = 0.03) and the RRT between 1985 and 1999 (OR = 3.6, p = 0.05) as predictors of long-term mortality.
RRT represent a valid alternative in selected patients. Selection should be oriented on patients needing third transplant without extra hepatic sepsis and vasoactive drug support at moment of RRT. If necessary, fourth and fifth RRT could be performed with a decision made on case-by-case basis, despite a high post-operative mortality.
肝再次移植仍是移植失败复发患者的唯一选择。我们研究的目的是确定接受再次肝移植(RRT)患者的患者及移植物存活的预测因素。
1985年1月至2012年12月,法国维勒瑞夫市保罗·布罗塞医院对2477例患者实施了2940例肝移植手术。所有接受第三次、第四次和第五次移植的患者均纳入本研究并进行回顾性分析。
单因素分析中,与术后90天患者存活相关的因素有术前血管升压药支持、术前肝外脓毒症、作为RRT指征的原发性无功能(PNF)、终末期肝病受体模型(MELD)、紧急RRT、RRT时的肌酐值及凝血酶原比率。多因素逻辑回归证实全身脓毒症状态(OR = 12.8,p = 0.01)和血管升压药支持(OR = 4.7,p = 0.05)作为术后死亡率预测因素的作用。单因素分析中,与患者10年长期存活相关的因素有血管升压药支持、全身脓毒症患者、作为RRT指征的PNF、1985年至1999年间发生的RRT、受体的MELD、RRT时的肌酐值及凝血酶原比率。多因素逻辑回归证实全身脓毒症患者(OR = 6.4,p = 0.03)和1985年至1999年间的RRT(OR = 3.6,p = 0.05)作为长期死亡率预测因素的作用。
RRT是特定患者的有效选择。选择应针对RRT时不需要肝外脓毒症和血管活性药物支持的第三次移植患者。如有必要,尽管术后死亡率高,但第四次和第五次RRT可根据具体情况逐案决定是否进行。